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  Open Access   
Abstract 
Background: Respiratory syncytial virus (RSV) is one of the major viruses 
that cause respiratory infections in all generations, not only in neonates and 
infants. There is a limited number of reports on serological epidemiology of 
RSV subgroups A and B. Neutralizing test (NT) antibody reflects protective 
immunity but bothersome. Sero-epidemiological study should be performed 
using practical NT method. Methods: Two wild-type viruses subgroups A 
and B, isolated in 2013, and the Long strain was used as the challenge viruses. 
NT antibody with 100% inhibition of cytopathic effect (CPE) was examined. 
A total of 91 serum samples obtained from 0 to 12 years subjects without 
RSV infection who visited our hospital with some health problems and 121 
sera obtained from healthy subjects in different age groups were used. Sero- 
logical epidemiology of subgroups A and B was investigated in this study us- 
ing new NT methods. Results: 1) A simple and practical NT method was de- 
veloped. 2) The NT antibody titer was lowest in <1 year of age (5 × 21.70 ± 2.03 
against subgroup A and 5 × 20.85 ± 1.31 against subgroup B) and increased in 3 
years of age or older, and high antibody titers were maintained during school 
age. 3) A slight difference was observed in the NT antibody titers against 
subgroups A and Bin young children <3 years, but not after 3 years of age, re- 
flecting the repeated infections. 4) Specific IgG antibody against RSV was 
measured. The IgG EIA values decreased with age. No association was ob- 
served between IgG EIA and NT titers. Conclusions: A simple NT assay me- 
thod was developed in the present study. By the age of 3 years, high NT anti- 
body titers were observed and maintained until 12 years. The IgG (EIA) val- 
ues decreased with age. No association was observed between IgG (EIA) and 
NT titers. 
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1. Introduction 
Respiratory syncytial virus (RSV) is a common viral pathogen for lower respira- 
tory tract infection in infants and young children [1], and especially causes se- 
rious pneumonia and bronchiolitis in newborn infants with preterm, congenital 
heart diseases, and immunocompromised illnesses [2] [3] [4] [5]. RSV also 
causes lower respiratory infection in the elderly as well as young infants [6]. Al- 
most 70% of children are infected with RSV by one year of age and approx- 
imately 100% by two years of age [1]. Repeat infections induce strong immunity, 
and thereafter it causes mild respiratory illness [1]. Previous studies showed that 
neutralizing antibody (NT) is related to immune memory to prevent serious 
lower respiratory tract infections [7]. Palivizumab, the specific neutralizing hu- 
manized monoclonal antibody, is used for prophylaxis in infants and young 
children with an increased risk of hospitalization due to serious complications of 
RSV [8]. Palivizumab is effective but expensive, with monthly administration 
during the outbreak season. 
There are two subgroups, A and B, with different antigenic properties [9]. 
During an outbreak, several genotypes were found [10]. High levels of serum an- 
tibodies do not always prevent infection, and clinical reinfections with the same 
RSV subgroup were reported [11]. For subgroup A, at least ten genotypes (GA1-
GA7, SAA1, NA1, and NA2) have been described, and recently ON1 with a 72-
nucleotide insertion in the G genome was reported [12]. Like subgroup A, a 60-
nucleotide insertion in the G genome was identified in subgroup B [13]. New 
genotypes have recently become dominant [14]. The antigenicity of new geno- 
types is of marked concern. It is necessary to examine NT antibody against each 
subgroup to evaluate the immunity. 
RSV is a common pathogen, with an estimated 33 million patients with se- 
rious RSV infection in a year, 3 million hospitalizations, and 60,000 deaths in 
children aged <5 years globally [15]. However, there is no licensed vaccine at 
present. The development of a safe and effective RSV vaccine has been antic- 
ipated. A sero-epidemiological survey is required to evaluate the background of 
RSV immune status for the target generations for developing RSV vaccine. The 
neutralization test (NT) and enzyme immunoassay (EIA) have been employed in 
sero-epidemiological studies. NT is the most reliable method for evaluating vac- 
cine immunogenicity, performing sero-prevalence studies, and detecting infec- 
tion with a significant 4-fold increase. However, NT test is time-consuming and 
troublesome experiment and requires skillful experience. The purpose of the 
study is to develop the sophisticated NT method and to perform serological epi- 
demiology of subgroups A and B. 
2. Materials and Methods 
2.1. Subjects 
We obtained 91 sera from patients aged 0 to 12 years who were hospitalized in 
Tama-Hokubu Medical Center from May to August 2014 with some medical 
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problems, such as urinary tract infection, Kawasaki disease, asthma, and respi- 
ratory tract infections without detection of RSV using the rapid diagnosis kit. 
Patients with RSV infection and those with medical history of administration of 
palivizumab were excluded from the study. 
A total of 121 sera of healthy children, consisting of approximately 10 subjects 
for each year of age, were previously obtained for serological investigation in 
different age groups to assess the serological background of vaccine preventable 
diseases. The purpose of the study was explained to the parents and written in- 
formed consent was obtained from all participants and their guardians. The Re- 
search Ethical Committee of Tama-Hokubu Medical Center approved this study, 
with the registration 25-18/2014. The sera were stored at −20˚C. 
2.2. Respiratory Syncytial Virus Strain 
The wild-type viruses were isolated from patients with a positive result using the 
rapid RS kit (check RSV® SA Scientific, Inc. San Antonio, Texas/ USA), and sub- 
groups A and B were identified by genomic analysis. We assessed the genetic va- 
riability of RSV subgroups by restriction fragments analysis of PCR products 
and/or nucleotide sequence determination of part of the N protein gene [16]. 
We selected two clinical isolates in the epidemic period of 2013, representative of 
subgroups A and B as the challenge viruses. 
2.3. Virus Infectivity 
Infectivity was determined based on the 50% tissue culture infective dose 
(TCID50) in Vero cells. The virus culture fluid was serially diluted by 10-fold and 
a confluent monolayer of Vero cells was infected with 50 μL of each dilution in 
96-well plates in MEM supplemented with 2% FBS. The plates were incubated 
for 7 days at 33˚C in 5% CO2. 
2.4. Enzyme Linked Immunosorbent Assay (EIA) 
Serum IgG antibodies against RSV (subgroup A) were measured by indirect EIA. 
The 96-well plate was coated with RSV (subgroup A) culture fluid overnight. 
After  washing,  the  wells  were  blocked  with  Blocking  One®  (Nacalai  Tesque, 
Kyoto, Japan). Serum samples were diluted at 1:200 and 100 μL was applied to 
the well. As the enzyme-conjugated secondary antibody, 1000-fold dilution of 
Anti Human-IgG (H + L) goat serum conjugated horseradish peroxidase (Gene 
Tex, Inc., Irvine, California/USA) was used. After washing and incubating the 
plate with the substrate solution, the reaction was stopped, and absorbance was 
read at 450 nm in a spectrophotometer. 
2.5. Neutralizing Antibody Titers (NT) 
NT antibody was measured based on the 100 percent inhibition of cytopathic ef- 
fect (CPE). Serum samples were inactivated at 56˚C for 30 mins and serially di- 
luted by two-fold, starting from 1:10 dilution. They were mixed with an equal 
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volume of the challenge virus containing 50 - 100 TCID50. Fifty microliters of 
mixture were subsequently placed on the monolayer of Vero cells in a 96-well 
plate. The plate was incubated for 7 days and fixed with 95% ethanol. The plate 
was stained with goat anti-RSV polyclonal antibody (Abcam® Cambridge, Eng- 
land/UK) diluted to 1:1500, and then donkey anti-goat IgG antibody conjugated 
with horseradish peroxidase (Santa Cruz Biotechnology, Inc., Dallas, Tex- 
as/USA) diluted to 1:1500 was added. CPE was visualized using the Peroxidase 
Stain DAB kit with Metal enhancer for DAB staining (Nacalai Tesque, Inc., 
Kyoto, Kyoto/Japan). The NT titer is expressed as the reciprocal of the highest 
dilutions, which showed 100% inhibition of CPE. 
2.6. Statistical analysis 
Data analyses were done using Statcel 3 on Excel (OMS Publishing, Tokorozawa, 
Saitama/Japan). Serum IgG antibodies against RSV were analyzed using a simple 
regression analysis. Correlations were examined using Spearman’s correlation 
coefficient by rank test. 
3. Results 
3.1. Distribution of RSV Subgroups 
The distribution of RSV subgroups A and B was examined in 32 hospitalized pa- 
tients in our hospital from July in 2013 to March in 2014. The results are shown 
in Figure 1. Subgroup A was detected in 12 (37.5%), subgroup B in 17 (53.1%), 
and 3 (9.3%) were unidentified. The circulating strains have similar sequences 
for each subgroup. The circulating strains were conventional genotypes without 
insertion in the sequence, not a new one (ON1 or BA). 
 
Figure 1. Distribution of RSV subgroups in Tokyo in the 2013/2014 season. Subgroups A 
and B were identified by restriction fragment length polymorphism and analyzed by nuc- 
leotide sequence determination of part of the N protein gene. 
DOI: 10.4236/ojped.2020.103055 546 Open Journal of Pediatrics  
M. Niida et al. 
 
3.2. RSV EIA Antibodies in Healthy Children 
The results of IgG (EIA) antibodies against RSV (subgroup A) in 91 hospitalized 
patients without detection of RSV using the rapid diagnosis kit are shown in dif- 
ferent age groups in Figure 2(a) and those of 121 healthy children in Figure 
2(b). The IgG antibody titer decreased in the older age group. The regression 
lines of each group were as follows: IgG-0.02908 × age + 0.629549 (p = 0.096) 
(Figure 2(a)), IgG = −0.0466 × age + 0.86832 (p = 0.001) (Figure 2(b)). 
3.3. RSV NT Antibody in Healthy Children 
We developed an immunostaining method for the NT assay, and CPE was visi- 
ble as black spots on a 96-well plate (Figure 3(a) and Figure 3(b)). The spots 
were confirmed as RSV-specific CPE by DAB staining, using anti-RSV monoc- 
lonal antibody (Figure 3(c)). The results of two serum examples (#1 and #2) are 
shown in Figure 3(a). Serum #1 showed CPE at a 1:80 dilution and higher and 
the NT titer was determined as 1:40. Serum sample #2 was negative. The com- 
plete inhibition NT antibody titers were examined. 
The NT titers of 91 patients hospitalized without RSV infection against sub- 
groups A and B are shown in Figure 4(a) and Figure 4(b), respectively. NT an- 
tibody titers are shown for each age (from 0 to 5 years) and the group from 6 to 
10 years old. The mean antibody titer was lowest in <1-year infants (mean ± SD: 
5 × 21.70 ± 2.03 against subgroup A, and 5 × 20.85 ± 1.31 against subgroup B) and the ti- 
ter showed a higher level after 2 years of age. Mean NT antibody titers were low- 
er against subgroup B than those against subgroup A. 
 
Figure 2. Serum IgG (EIA) antibodies against RSV at different ages. Dots show individual 
serum IgG (EIA) antibodies against RSV. (a) 91 patients hospitalized without RSV infec- 
tion, (b) 121 healthy children. 
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Figure 3. NT assay using immune staining. NT antibody titers were examined by com- 
plete inhibition of CPE. The black spots were confirmed as the DAB staining using goat 
anti RSV antibody and anti-goat IgG antibody raised in the donkey labelled with perox- 
idase. (a) Serum #1 showed CPE at a 1:80 dilution and higher, the NT titer was 1:40, and 
#2 was negative. (b) DAB staining of 96-well plates. (c) CPE is magnified. 
 
Figure 4. The NT antibody titer at different ages against subgroups A (upper panel) and 
B (lower panel) in 91 patients hospitalized without RSV infection. The dots indicate indi- 
vidual antibody titers, and bars indicate mean values with 1.0 SD. 
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A total of 121 healthy children from 1 to 10 years old were examined. The 
change in NT titers against subgroups A and B is shown in Figure 5(a) and 
Figure 5(b), respectively. High NT antibody titers were observed at 3 years of 
age against both subgroups. 
A moderate correlation was observed between NT titers against a circulating 
strain (wild subgroup A) and those against another circulating strain (wild sub- 
group B) with a correlation coefficient of 0.69. However, there was lower corre- 
lation between NT titers against a circulating strain (wild subgroup A) and the 
Long strain (r = 0.35) (data not shown). 
4. Discussion 
The NT assay procedure is complicated and requires skillful experiences. The 
most time-consuming and critical stage of the test is the final observation of CPE 
under a microscope or counting the number of plaques. To simplify this step, 
CPE was visualized with the naked eye, using polyclonal antibody against RSV 
and a peroxidase staining kit. Spots developed with the peroxidase staining kit 
were easy to identify even by an untrained person, and we were able to accurate- 
ly examine all wells in a short time, as with CPE determination under a micro- 
scope. 
Using this NT test, serological surveillance was performed. The NT antibody 
titer was lowest in infants <1 year. There were few exposure opportunities due to 
being the pre-season or maternal conferred immunity. Even if they are infected, 
 
Figure 5. The neutralizing antibody titer with age against subgroups A and B in 121 
healthy children. The antibody titers of NT against subgroups A (upper panel) and B 
(lower panel) are shown from 1 to 10 years old. Antibody responses are shown in box-
and-whisker plots with the mean ± 1.0 SD. 
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it is difficult for infants <1-year-old to show a sufficient antibody response be- 
cause of the immaturity of acquired immune responses [17]. By the age of 2 
years, repeat infections result in elevated antibody titers in most children. 
Children >2 years old produce durable antibodies and maintain high-level titers. 
Children aged <1 year have conferred antibodies from the mother [18]. How- 
ever, in this study, the neutralizing antibody titer was lowest in infants <1 year, 
since the mean ± SD of the age in months in infants <1 year was 7.90 ± 3.11. 
Maternally derived specific antibodies declined and, therefore, the geometric 
mean titer was low. A more precise study is required to confirm the maternally 
conferred NT levels with decay caused by aging. 
The antibody titers of IgG against RSV declined in older children. Generally, 
the severity of illness caused by RSV infection decreases in older children [19]. 
The antibody titers do not represent factors reducing the severity of infection. 
On the other hand, NT antibody titers were low in infants<1 year and titers rose 
after infancy. Only NT antibody is not associated with protective immune activ- 
ity [20] [21], and we should examine nasal IgA antibody and cellular immunity. 
Repeat infections and exposure to RSV antigens induce strong immunity, but 
the cross-reactivity of the immune response against individual subgroup viruses 
has been inadequately elucidated [22]. The NT activity corresponds specifically 
to an individual virus, and cross-reactivity is observed in some viruses, such as 
RSV subgroups A and B [23]. It is important to possess sufficient levels of NT 
antibody against the latest circulating strains and those against the new geno- 
types need to be studied. 
Cellular immunity is important, along with neutralizing activity, to prevent 
infection, but there is no practical method to assess the immunity in a clinical 
setting. A previous study showed that RSV-specific nasal IgA was more signifi- 
cantly correlated with protection than serum neutralizing antibody [24], but vi- 
rus-specific IgA antibodies are shorter lived than serum IgG antibodies, being 
detectable for only a few months following infection [25]. Both serum and se- 
cretory antibodies are induced in response to RSV infection, even in young in- 
fants. However, the frequency and magnitude of the antibody response were sig- 
nificantly lower in young infants than in older infants and children [26]. Serum 
antibodies were low at younger than one year of age, even after the primary in- 
fection. Reinfection enhanced the antibody levels, and thus sustained the im- 
munity [21]. 
The serum neutralizing antibodies to the G protein are RSV subgroup-specific 
[22]. In contrast, antibodies to the fusion (F) protein are cross-reactive between 
RSV subgroups [27]. It has been suggested that a weak response of antibody to G 
protein of the heterologous group in the respiratory tract may determine rein- 
fection with other RSV strains. The vaccines inducing both IgA and serum neu- 
tralizing antibody responses to the F protein are more protective and versatile. 
To evaluate the efficacy of the vaccine, there is a need to conduct serological 
surveillance of protective antibody levels before vaccine use. Surveillance of 
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whole populations is important, but there are no data on what level of neutrali- 
zation activity is clinically effective. By examining children with different levels 
of severity depending on their age, it may be possible to deduce effective protec- 
tion levels. Once a clinically effective level of neutralizing activity is known, it 
may be applicable as a surrogate marker of vaccine efficacy. To evaluate the use- 
fulness of the vaccine in the future, it will be necessary to widely investigate the 
age-specific neutralizing antibody titer against each subgroup. 
In conclusion, a simple and practical NT assay method was developed. NT ti- 
ters were low in those <1 year of age and showed high levels after 3 years of age. 
NT titers against subgroup A were higher than against subgroup B. 
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